Regularly monitor serum calcium and phosphorus levels. Target ranges vary depending on the individual’s specific condition, but generally aim for calcium within the normal range (8.5-10.5 mg/dL) and phosphorus within the desirable range (2.5-4.5 mg/dL).
Frequency of monitoring depends on the patient’s stability and response to therapy. Initially, more frequent checks (e. g., weekly) may be needed, gradually reducing to monthly or even less frequent monitoring as the patient stabilizes. Parathyroid hormone (PTH) levels should also be monitored to assess the effectiveness of treatment.
Adjust the oral calcitriol dosage based on lab results and clinical presentation. Small incremental dosage adjustments are recommended to avoid significant fluctuations in calcium and phosphorus. Never adjust the dose without consulting with the healthcare provider.
Observe for signs and symptoms of hypercalcemia (e. g., nausea, vomiting, constipation, fatigue, polyuria, polydipsia) or hyperphosphatemia (e. g., muscle weakness, loss of appetite, confusion). If these occur, promptly reduce the dosage or temporarily suspend treatment.
Consider other factors influencing calcium and phosphorus levels, such as diet, medications, and underlying medical conditions. Adjustments may need to be made based on these factors.
| Serum Calcium | Initially weekly, then monthly as needed | 8.5-10.5 mg/dL | Adjust dose; consult healthcare provider |
| Serum Phosphorus | Initially weekly, then monthly as needed | 2.5-4.5 mg/dL | Adjust dose; consult healthcare provider |
| Parathyroid Hormone (PTH) | As clinically indicated | Age and condition-specific | Adjust dose; consult healthcare provider |
Regular communication between the patient and healthcare provider is crucial for optimal management. Report any changes in symptoms or lab values immediately.
